Major difference between Donepezil and A-273 is the side effects. If the two were hypothetically equal, just on less side effects, we would have a new SOC if p2/3 repeats its p2a/b results.
However, we all know Donepezil doesn't work for a year, more like a month or two before the decline starts again.
Plus, we don't know exactly HOW much a-273 does benefit, or as the naysayers say, if it benefits at all, the patient because the dosage isn't optimized across the board. Some need to understand that and not treat this data as "as good as it gets".
We are yet to see just how good a-273 works when given with the correct dosage.